Cargando…
Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
BACKGROUND: Direct-acting oral anticoagulants (DOACs) are alternatives to low molecular weight heparin (LMWH) in most cancer-associated thrombosis (CAT) patients. OBJECTIVES: This study sought to compare the effectiveness and safety of rivaroxaban and LMWH for venous thromboembolism (VTE) treatment...
Autores principales: | Coleman, Craig I., Caroti, Kimberly Snow, Abdelgawwad, Khaled, Psaroudakis, George, Fatoba, Samuel, Rivera, Marcela, Schaefer, Bernhard, Brobert, Gunnar, Khorana, Alok A., Becattini, Cecilia, Lee, Agnes Y.Y., Ekbom, Anders, Carrier, Marc, Brescia, Christopher, Cohen, Alexander T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152194/ https://www.ncbi.nlm.nih.gov/pubmed/37144109 http://dx.doi.org/10.1016/j.jaccao.2022.10.014 |
Ejemplares similares
-
Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program
por: Caroti, Kimberly Snow, et al.
Publicado: (2023) -
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023) -
Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Cancer
por: Shabtaie, Samuel A., et al.
Publicado: (2023) -
A Picture Is Worth 2,000 Words
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2023) -
Arterial Thromboembolism in Patients With AF and CHA(2)DS(2)-VASc Score 0-2 With and Without Cancer
por: Leader, Avi, et al.
Publicado: (2023)